CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that members of its management team will present a corporate overview and participate in a panel discussion at upcoming investor conferences. Details are as follows:
Stifel 2016 Healthcare Conference
Date: Tuesday, November 15
Presentation
Time: 1:30 p.m. ET
Location: The Lotte New York Palace Hotel, 455
Madison Avenue, New York, NY
28th Annual Piper Jaffray Healthcare
Conference
Date: Wednesday, November 30
Panel Title: Genomic
3.0 Panel
Panel Time: 12:00-12:55 p.m. ET
Location: The
Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY
A live webcast of the Stifel presentation will be available on the News & Investors section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor with potential in a range of solid tumors and blood cancers.
Led by a team with deep experience in drug discovery, development and
commercialization, Syros is located in Cambridge, Mass.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161108005090/en/
Media Contact:
Syros Pharmaceuticals, Inc.
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com
Source: Syros Pharmaceuticals
Released November 8, 2016